logo
Share SHARE
FONT-SIZE Plus   Neg

Optimer Terminates Michael Chang As Chairman, John Prunty As CFO

Optimer Pharmaceuticals (OPTR) Monday said it removed Michael Chang as chairman, terminated John Prunty as chief financial officer and Youe-Kong Shue as vice president. The terminations are related to lapses in compliance and conflict in its relationship with its 43 percent-owned Taiwanese-based independent affiliate - Optimer Biotechnology, Inc. or OBI.

Hank McKinnell, lead independent director, will be the new Chairman and Kurt Hartman, general counsel, chief compliance officer and senior vice president, will be the acting chief financial officer.

Optimer stated that the removal of Chang as chairman was based on his actions in his capacity as Optimer's representative on the board of OBI as well as his failure to identify and effectively manage compliance, record keeping and conflict of interest issues in connection with OBI's grant of 1.5 million shares of OBI to Chang. Optimer's assessment is that the grant of shares is potentially for the benefit of a third party.

According to Optimer, the changes are not expected to materially impact its revenues or operations, including the commercialization and launch of Dificid. In May 2011, the U.S. Food and Drug Administration had approved its antibiotic Dificid for the treatment of Clostridium difficile infection in adult patients, making it the first drug to be cleared in nearly thirty years to treat the disease.

Further, based upon preliminary results, the company expects to report first-quarter gross revenues of around $16.45 million. This represents an increase of nearly 36 percent over the sequential fourth quarter, the company added.

OPTR is currently trading at $13.58, down $0.71 or 4.97 percent, on a volume of 409 thousand shares on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Nestle SA's shares were gaining around 4 percent in Zurich trading after billionaire activist investor Daniel Loeb's hedge fund Third Point LLC bought a $3.5 billion stake in the Swiss food giant. The acquisition of about 1.25% stake in Nestle would put pressure on the company to find ways to accelerate growth. We believe this stock is well-positioned for at least 15% upside from current $23 levels. The stock featured on our premium product Short-Term Investor on April 25 at an opening price of $19.5, and on June 9 touched an intra-day high of $29.73, returning a gain of 52.4% to investors. It is now at an attractive price point again. Takata Corp., the Japanese manufacturer of faulty air bag inflators linked to the deaths of at least 16 people, has filed for bankruptcy protection in Tokyo and the US following billions of dollars in liabilities linked to a massive global recall. Takata also agreed to sell its global assets and operations to US auto parts maker Key Safety Systems, owned by China's Ningbo Joyson Electronic.
comments powered by Disqus
Follow RTT